WHO PACKAGE INSERT

NAME OF THE MEDICINAL PRODUCT

Boostrix™
Diphtheria, tetanus and pertussis (acellular, component) vaccine (adsorbed, reduced antigen(s) content)

QUALITATIVE AND QUANTITATIVE COMPOSITION

One dose (0.5 ml) of Boostrix™ contains:

- Diphtheria toxoid¹ not less than 2 International Units (IU) (2.5 Lf)
- Tetanus toxoid¹ not less than 20 International Units (IU) (5 Lf)
- Bordetella pertussis antigens
  - Pertussis toxoid¹ 8 micrograms
  - Filamentous Haemagglutinin¹ 8 micrograms
  - Pertactin¹ 2.5 micrograms

¹ Adsorbed on aluminium hydroxide, hydrated (Al(OH)_3) and aluminium phosphate (AlPO_4)

Excipients: sodium chloride, water for injections.

Boostrix™ is a turbid white suspension for injection. Upon storage, a white deposit and clear supernatant can be observed.

Formaldehyde, polysorbate 80 and glycine are present as residuals from the manufacturing process.

CLINICAL PARTICULARS

Therapeutic indications

Boostrix™ is indicated for booster vaccination against diphtheria, tetanus and pertussis of individuals from the age of four years onwards.

Posology and method of administration

Posology

A single 0.5 ml dose of the vaccine is recommended.
Boostrix™ can be given in accordance with the current local medical practices for booster vaccination with adult-type combined diphtheria-tetanus vaccine, when a booster against pertussis is desired.

Repeat vaccination against diphtheria, tetanus and pertussis should be performed at intervals as per official recommendations (generally 10 years).

Boostrix™ can be used in the management of tetanus prone injuries in persons who have previously received a primary vaccination series of tetanus toxoid vaccine. Tetanus immunoglobulin should be administered concomitantly in accordance with official recommendations.

Method of administration

Boostrix™ is for deep intramuscular injection, preferably in the deltoid region (see also Special warnings and precautions for use).

Contraindications

Boostrix™ should not be administered to subjects with known hypersensitivity to any component of the vaccine (see Qualitative and Quantitative composition), or to subjects having shown signs of hypersensitivity after previous administration of diphtheria, tetanus or pertussis vaccines.

Boostrix™ is contra-indicated if the subject has experienced an encephalopathy of unknown aetiology, occurring within 7 days following previous vaccination with pertussis-containing vaccine. In these circumstances pertussis vaccination should be discontinued and the vaccination course should be continued with diphtheria and tetanus vaccines.

Boostrix™ should not be administered to subjects who have experienced transient thrombocytopenia or neurological complications following an earlier immunisation against diphtheria and/or tetanus (for convulsions or hypotonic-hyporesponsive episodes, see Special warnings and precautions for use).

Special warnings and precautions for use

As with other vaccines, administration of Boostrix™ should be postponed in subjects suffering from acute severe febrile illness. The presence of a minor infection is not a contra-indication.

Vaccination should be preceded by a review of the medical history (especially with regard to previous vaccination and possible occurrence of undesirable events) and a clinical examination.

If any of the following events are known to have occurred in temporal relation to receipt of pertussis-containing vaccine, the decision to give doses of pertussis-containing vaccines should be carefully considered:
• temperature of ≥ 40.0°C within 48 hours of vaccination, not due to another identifiable cause;
• collapse or shock-like state (hypotonic-hypo-responsiveness episode) within 48 hours of vaccination;
• persistent, inconsolable crying lasting ≥ 3 hours, occurring within 48 hours of vaccination;
• convulsions with or without fever, occurring within 3 days of vaccination.

In children with progressive neurological disorders, including infantile spasms, uncontrolled epilepsy or progressive encephalopathy, it is better to defer pertussis (Pa or Pw) immunization until the condition is corrected or stable. However, the decision to give pertussis vaccine must be made on an individual basis after careful consideration of the risks and benefits.

As with all injectable vaccines, appropriate medical treatment and supervision should always be readily available in case of a rare anaphylactic reaction following the administration of the vaccine.

Boostrix™ should be administered with caution to subjects with thrombocytopenia or a bleeding disorder since bleeding may occur following an intramuscular administration to these subjects. Firm pressure should be applied to the injection site (without rubbing) for at least two minutes.

A history or a family history of convulsions and a family history of an adverse event following DTP vaccination do not constitute contra-indications.

Human Immunodeficiency Virus (HIV) infection is not considered as a contra-indication for diphtheria, tetanus and pertussis vaccination. The expected immunological response may not be obtained after vaccination of immunosuppressed patients.

Extremely rare cases of collapse or shock-like state (hypotonic-hypo-responsiveness episode) and convulsions within 2 to 3 days of vaccination have been reported in DTPa and DTPa combination vaccines.

Boostrix™ should under no circumstances be administered intravenously.

Syncope (fainting) can occur following, or even before, any vaccination as a psychogenic response to the needle injection. It is important that procedures are in place to avoid injury from faints.

As with any vaccine, a protective immune response may not be elicited in all vaccinees.

**Interaction with other medicinal products and other forms of interaction**

Concomitant use with other inactivated vaccines and with immunoglobulin is unlikely to result in an interference with the immune responses.
When considered necessary, *Boostrix™* can be administered simultaneously with other vaccines or immunoglobulins.

If *Boostrix™* is to be given at the same time as another injectable vaccine or immunoglobulin, the products should always be administered at different sites.

As with other vaccines, patients receiving immunosuppressive therapy or patients with immunodeficiency may not achieve an adequate response. In these patients, when tetanus vaccine is needed for tetanus prone wound, plain tetanus vaccine will be used.

**Pregnancy and lactation**

**Pregnancy**
As with all inactivated vaccines, one does not expect harm for the foetus. However, adequate human data on use of this pertussis containing vaccine during pregnancy are not available.

Therefore, *Boostrix™* should be used during pregnancy only when clearly needed, and the possible advantages outweigh the possible risks for the foetus. When protection against tetanus is sought, consideration should be given to a licensed tetanus or combined diphtheria-tetanus vaccine.

**Lactation**
The safety of *Boostrix™* when administered to breast-feeding women has not been evaluated.

It is unknown whether *Boostrix™* is excreted in human breast milk.

*Boostrix™* should only be used during breast-feeding when the possible advantages outweigh the potential risks.

**Undesirable effects**

Frequencies per dose are defined as follows:

- **Very common:** $\geq 10\%$
- **Common:** $\geq 1\%$ and $< 10\%$
- **Uncommon:** $\geq 0.1\%$ and $< 1\%$
- **Rare:** $\geq 0.01\%$ and $< 0.1\%$
- **Very rare:** $< 0.01\%$

**Clinical trial data**

**Children from 4 to 9 years of age**

**Infections and infestations**
Uncommon: upper respiratory tract infection

**Metabolism and nutrition disorders**
Common: anorexia

**Psychiatric disorders**
Very common: irritability

**Nervous system disorders**
Very common: somnolence
Common: headache
Uncommon: disturbances in attention

**Eye disorders**
Uncommon: conjunctivitis

**Gastrointestinal disorders**
Common: diarrhoea, vomiting, gastrointestinal disorders

**Skin and subcutaneous tissue disorders**
Uncommon: rash

**General disorders and administration site conditions**
Very common: injection site reactions (including pain, redness and swelling), fatigue
Common: fever ≥ 37.5 °C (including fever > 39 °C),
Uncommon: other injection site reactions (such as induration), pain

**Adults, adolescents and children from the age of 10 years onwards**

**Infections and infestations**
Uncommon: upper respiratory tract infection, pharyngitis

**Blood and lymphatic system disorders**
Uncommon: lymphadenopathy

**Nervous system disorders**
Very common: headache
Common: dizziness
Uncommon: syncope

**Respiratory, thoracic and mediastinal disorders**
Uncommon: cough

**Gastrointestinal disorders**
Common: nausea, gastrointestinal disorders
Uncommon: diarrhoea, vomiting

**Skin and subcutaneous tissue disorders**
Uncommon: hyperhidrosis, pruritus, rash

**Musculoskeletal and connective tissue disorders**
Uncommon: arthralgia, myalgia, joint stiffness, musculoskeletal stiffness

**General disorders and administration site conditions**
Very common: injection site reactions (including pain, redness and swelling), fatigue, malaise
Common: fever ≥ 37.5 °C, injection site reactions (such as injection site mass and injection site abscess sterile)
Uncommon: fever > 39 °C, influenza like illness, pain

**Post-marketing surveillance**

**Blood and lymphatic system disorders**
Rare: angioedema

**Immune system disorders**
Very rare: allergic reactions, including anaphylactic and anaphylactoid reactions

**Nervous system disorders**
Rare: convulsions (with or without fever)

**Skin and subcutaneous tissue disorders**
Rare: urticaria

**General disorders and administration site conditions**
Rare: extensive swelling of the vaccinated limb, asthenia

Data on 146 subjects suggest a small increase in local reactogenicity (pain, redness, swelling) with repeated vaccination according to a 0, 1, 6 months schedule in adults (> 40 years of age).

Subjects fully primed with 4 doses of DTPw followed by a Boostrix™ dose around 10 years of age show an increase of local reactogenicity after an additional Boostrix™ dose administered 10 years later.

**PHARMACOLOGICAL PROPERTIES**

**Pharmacodynamic properties**

Pharmaco-therapeutic group: Bacterial vaccines combined, ATC code J07AJ52

Immune response results to the diphtheria, tetanus and acellular pertussis components in clinical studies are presented in the table below. Approximately one month following booster vaccination with Boostrix™, the following seroprotection / seropositivity rates were observed:
<table>
<thead>
<tr>
<th>Antigen</th>
<th>Seroprotection / Seropositivity</th>
<th>Adults and adolescents from the age of 10 years onwards, at least 690 subjects (% vaccinees)</th>
<th>Children from 4 to 9 years of age, at least 415 subjects (% vaccinees)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diphtheria</td>
<td>≥ 0.1 IU/ml*</td>
<td>97.2%</td>
<td>99.8%</td>
</tr>
<tr>
<td>Tetanus</td>
<td>≥ 0.1 IU/ml*</td>
<td>99.0%</td>
<td>100.0%</td>
</tr>
<tr>
<td>Pertussis:</td>
<td>- Pertussis toxoid</td>
<td>≥ 5 EL U/ml</td>
<td>97.8%</td>
</tr>
<tr>
<td></td>
<td>- Filamentous haemagglutinin</td>
<td>≥ 5 EL U/ml</td>
<td>99.9%</td>
</tr>
<tr>
<td></td>
<td>- Pertactin</td>
<td>≥ 5 EL U/ml</td>
<td>99.4%</td>
</tr>
</tbody>
</table>

*cut-off accepted as indicative of protection

Results of the comparative studies with commercial dT vaccines indicates that the degree and duration of protection would not be different from those obtained with these vaccines.

**Protective efficacy of pertussis**

There is currently no correlate of protection defined for pertussis; however, the protective efficacy of GlaxoSmithKline Biologicals' DTPa (Infanrix™) vaccine against WHO-defined typical pertussis (≥ 21 days of paroxysmal cough with laboratory confirmation) was demonstrated in the following 3-dose primary studies:

- a prospective blinded household contact study performed in Germany (3, 4, 5 months schedule). Based on data collected from secondary contacts in households where there was an index case with typical pertussis, the protective efficacy of the vaccine was 88.7%. Protection against laboratory confirmed mild disease, defined as 14 days or more of cough of any type was 73% and 67% when defined as 7 days or more of cough of any type.
- an NIH sponsored efficacy study performed in Italy (2, 4, 6 months schedule). The vaccine efficacy was found to be 84%. When the definition of pertussis was expanded to include clinically milder cases with respect to type and duration of cough, the efficacy of Infanrix™ was calculated to be 71% against >7 days of any cough and 73% against >14 days of any cough.

Vaccinees receiving Boostrix™ achieved anti-pertussis antibody titres greater than those in the German household contact study where the protective efficacy was 88.7%.

Five to 6 years following vaccination with Boostrix™, at least 94% of children from the age of 4 years onwards were seroprotected or seropositive against all vaccine components, except for the pertussis toxoid component (52% of subjects were seropositive against pertussis toxoid).

Ten years following vaccination with Boostrix™, at least 86% of adults were seroprotected or seropositive against all vaccine components.

In adolescents, the percentage of subjects who were seroprotected or seropositive was at least 82% against all vaccine components, except for the pertussis toxoid component (61% of subjects were seropositive against pertussis toxoid).
The immunogenicity of *Boostrix™*, administered 10 years after a previous booster dose with reduced-antigen content diphtheria, tetanus and acellular pertussis vaccine(s) has been evaluated. One month post vaccination, > 99% of subjects were seroprotected against diphtheria and tetanus and seropositive against pertussis.

In subjects ≥ 40 years of age that had not received any diphtheria or tetanus containing vaccine in the past 20 years (including those who have never been vaccinated or whose vaccination status was unknown), one dose of *Boostrix™* induced an antibody response against pertussis and protected against tetanus and diphtheria in the majority of cases. Two additional doses of a diphtheria and tetanus containing vaccine maximized the vaccine response against diphtheria and tetanus when administered one and six months after the first dose.

**PHARMACEUTICAL PARTICULARS**

**Incompatibilities**

*Boostrix™* should not be mixed with other vaccines in the same syringe.

**Shelf Life**

The expiry date is indicated on the label and packaging.

**Special precautions for storage**

Store in a refrigerator (2°C – 8°C). During transport, recommended conditions of storage must be respected.

Do not freeze; discard if vaccine has been frozen.

**Nature and contents of container**

*Boostrix™*: 0.5 ml of suspension in a vial (type I glass) for 1 dose with a stopper (butyl rubber) - pack sizes of 1, 10 and 100.

Not all pack sizes may be marketed.

**Special precautions for disposal and other handling**

Prior to vaccination, the vaccine should be well shaken in order to obtain a homogeneous turbid white suspension and visually inspected for any foreign particulate matter and/or variation of physical aspect prior to administration. In the event of either being observed, discard the vaccine.

The vaccine should be administered immediately after opening the container (not later than 8 hours after opening).
Any unused product or waste material should be disposed of in accordance with local requirements.

**Vaccine Vial Monitor (see VVM pictogram at the end of the leaflet)**

The Vaccine Vial Monitor (VVM) is part of the label used for all *Boostrix*™ batches supplied by GlaxoSmithKline Biologicals. The colour dot that appears on the label of the vial is a VVM. This is a time-temperature sensitive dot that provides an indication of the cumulative heat to which the vial has been exposed. It warns the end user when exposure to heat is likely to have degraded the vaccine beyond an acceptable level.

The interpretation of the VVM is simple. Focus on the central square. Its colour will change progressively. As long as the colour of this square is lighter than the colour of the ring, then the vaccine can be used. As soon as the colour of the central square is the same colour as the ring or of a darker colour than the ring, then the vial should be discarded.

It is absolutely critical to ensure that the storage conditions specified above (in particular the cold chain) are complied with. GlaxoSmithKline Biologicals will assume no liability in the event *Boostrix*™ has not been stored in compliance with the storage instructions. Furthermore GlaxoSmithKline Biologicals assumes no responsibility in case a VVM is defective for any reason.

![Diagram]

Inner square lighter than outer circle. **If the expiry date has not been passed, USE the vaccine.**

![Diagram]

At a later time, inner square still lighter than outer circle. **If the expiry date has not been passed, USE the vaccine.**

![Diagram]

**Discard point:** Inner square matches colour of outer circle. **DO NOT use the vaccine.**

![Diagram]

**Beyond the discard point:** Inner square darker than outer ring. **DO NOT use the vaccine.**

For further information, please contact the manufacturer.
Boostrix is a trademark of the GlaxoSmithKline group of companies.

<table>
<thead>
<tr>
<th>WHO Package Insert</th>
</tr>
</thead>
<tbody>
<tr>
<td>Version number: GDS006/WHO Insert01/ Date of issue: [MM/YYYY]</td>
</tr>
<tr>
<td>© 2013 GlaxoSmithKline Group of Companies</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Manufacturer:</th>
</tr>
</thead>
<tbody>
<tr>
<td>GlaxoSmithKline Biologicals s.a.</td>
</tr>
<tr>
<td>Rue de l’Institut 89, B-1330 Rixensart, Belgium.</td>
</tr>
<tr>
<td>Tel: (32.2) 656 81 11 Fax: (32.2) 656 80 00</td>
</tr>
</tbody>
</table>